A Frontiers in Cellular and Infection Microbiology study by Xu, Wu and colleagues projects chikungunya risk zones expanding from 21.3% to include northeastern North America, central Europe and East Asia by 2100 under multiple IPCC scenarios, driven primarily by Aedes albopictus niche shifts. The work relies on ecological niche modeling of >10,000 geo-referenced occurrence records rather than randomized trials, limiting causal inference while highlighting temperature and precipitation as dominant predictors; sample sizes for vector distributions are large yet uneven across continents, with potential publication bias from Asian and South American data sources. No conflicts of interest are declared, though all corresponding authors are affiliated with Chinese public-health institutions. This modeling extends earlier observational work, such as the 2019 Kraemer et al. Nature Microbiology analysis of Aedes albopictus range expansion under RCP 4.5 and 8.5 pathways (n=2,100+ occurrence points) and the 2022 WHO Global Vector Control Response report documenting chikungunya's 2005 Réunion outbreak mutation enabling albopictus transmission. The MedicalXpress coverage correctly flags the E1-A226V mutation but understates compounding risks from co-circulating dengue and Zika viruses sharing the same vectors, plus socioeconomic vulnerabilities in newly suitable temperate zones where immunity is absent. Public-health systems in predicted hotspots lack standardized Aedes surveillance protocols, a gap the Chinese team correctly identifies yet does not quantify in cost or workforce terms. Early monitoring by 2040 remains essential, yet models omit urban heat-island effects that could accelerate local transmission earlier than projected.